Repression of PFKFB3 Sensitizes Ovarian Cancer to PARP Inhibitors by Impairing Homologous Recombination Repair

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Date 2025 Jan 25

PMID 39863903

Authors

Yinan Xiao

Yu Wu

Qilong Wang

Mo Li

Chaolin Deng

Xiaoyang Gu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC), particularly high-grade serous ovarian carcinoma (HGSOC), is the leading cause of mortality from gynecological malignancies worldwide. Despite the initial effectiveness of treatment, acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPis) represents a major challenge for the clinical management of HGSOC, highlighting the necessity for the development of novel therapeutic strategies. This study investigated the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), a pivotal regulator of glycolysis, in PARPi resistance and explored its potential as a therapeutic target to overcome PARPi resistance.

Methods: We conducted in vitro and in vivo experiments to assess the role of PFKFB3 in OC and its impact on PARPi resistance. We analyzed PFKFB3 expression and activity in primary OC tissues and cell lines using western blotting and immunohistochemistry. CRISPR-Cas9 and pharmacological inhibitors were employed to inhibit PFKFB3, and the effects on PARPi resistance, homologous recombination (HR) repair efficiency, and DNA damage were evaluated. RNA sequencing and proximity labeling were employed to identify the molecular mechanisms underlying PFKFB3-mediated resistance. The in vivo efficacy of PARPi and PFK158 combination therapy was evaluated in OC xenograft models.

Results: PFKFB3 activity was significantly elevated in OC tissues and associated with PARPi resistance. Inhibition of PFKFB3, both genetically and pharmacologically, sensitized OC cells to PARPis, impaired HR repair and increased DNA damage. Proximity labeling revealed replication protein A3 (RPA3) as a novel PFKFB3-binding protein involved in HR repair. In vivo, the combination of PFK158 and olaparib significantly inhibited tumor growth, increased DNA damage, and induced apoptosis in OC xenografts without exacerbating adverse effects.

Conclusions: Our findings demonstrate that PFKFB3 is crucial for PARPi resistance in OC. Inhibiting PFKFB3 sensitizes HR-proficient OC cells to PARPis by impairing HR repair, leading to increased DNA damage and apoptosis. PFKFB3 represents a promising therapeutic target for overcoming PARPi resistance and improving outcomes in OC patients.

References

Jiang Y, Siu M, Wang J, Leung T, Chan D, Cheung A . PFKFB3 Regulates Chemoresistance, Metastasis and Stemness IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer. Front Oncol. 2022; 12:748403. PMC: 8837381. DOI: 10.3389/fonc.2022.748403. View

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Okamura N, Sakakibara R . A common phosphorylation site for cyclic AMP-dependent protein kinase and protein kinase C in human placental 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Biosci Biotechnol Biochem. 1998; 62(10):2039-42. DOI: 10.1271/bbb.62.2039. View

Paes Dias M, Moser S, Ganesan S, Jonkers J . Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021; 18(12):773-791. DOI: 10.1038/s41571-021-00532-x. View

Marsin A, Bouzin C, Bertrand L, Hue L . The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem. 2002; 277(34):30778-83. DOI: 10.1074/jbc.M205213200. View

Yi M, Ban Y, Tan Y, Xiong W, Li G, Xiang B . 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer. Mol Metab. 2018; 20:1-13. PMC: 6358545. DOI: 10.1016/j.molmet.2018.11.013. View

Yue W, Li X, Zhan X, Wang L, Ma J, Bi M . PARP inhibitors suppress tumours via centrosome error-induced senescence independent of DNA damage response. EBioMedicine. 2024; 103:105129. PMC: 11052917. DOI: 10.1016/j.ebiom.2024.105129. View

Konstantinopoulos P, Barry W, Birrer M, Westin S, Cadoo K, Shapiro G . Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019; 20(4):570-580. PMC: 7025391. DOI: 10.1016/S1470-2045(18)30905-7. View

Okar D, Manzano A, Navarro-Sabate A, Riera L, Bartrons R, Lange A . PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci. 2001; 26(1):30-5. DOI: 10.1016/s0968-0004(00)01699-6. View

10.

Feng Y, Wu L . mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival. Biochem Biophys Res Commun. 2017; 483(2):897-903. DOI: 10.1016/j.bbrc.2017.01.031. View

11.

Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y . An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A. 1999; 96(6):3047-52. PMC: 15892. DOI: 10.1073/pnas.96.6.3047. View

12.

Pilie P, Gay C, Byers L, OConnor M, Yap T . PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. Clin Cancer Res. 2019; 25(13):3759-3771. DOI: 10.1158/1078-0432.CCR-18-0968. View

13.

Rhee H, Zou P, Udeshi N, Martell J, Mootha V, Carr S . Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science. 2013; 339(6125):1328-1331. PMC: 3916822. DOI: 10.1126/science.1230593. View

14.

Shi L, Pan H, Liu Z, Xie J, Han W . Roles of PFKFB3 in cancer. Signal Transduct Target Ther. 2017; 2:17044. PMC: 5701083. DOI: 10.1038/sigtrans.2017.44. View

15.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

16.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

17.

Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N . EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition. Cancer Cell. 2020; 37(2):157-167.e6. PMC: 7155421. DOI: 10.1016/j.ccell.2019.12.015. View

18.

Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A . Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008; 7(1):110-20. DOI: 10.1158/1535-7163.MCT-07-0482. View

19.

De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong B, Cantelmo A . Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013; 154(3):651-63. DOI: 10.1016/j.cell.2013.06.037. View

20.

Xiao Y, Jin L, Deng C, Guan Y, Kalogera E, Ray U . Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer. Oncogene. 2021; 40(8):1409-1424. PMC: 7906909. DOI: 10.1038/s41388-020-01621-4. View